US Patent

US11744895 — Intranasal epinephrine formulations and methods for the treatment of disease

Method of Use · Assigned to Aegis Therapeutics LLC · Expires 2039-02-06 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating anaphylaxis with epinephrine products, specifically those adapted for nasal delivery.

USPTO Abstract

Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Drugs covered by this patent

Epipen (epinephrine) · Pfizer Inc.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3979`	—	Epipen
`U-3979`	—	Epipen

Patent Metadata

Patent number: US11744895
Jurisdiction: US
Classification: Method of Use
Expires: 2039-02-06
Drug substance claim: No
Drug product claim: No
Assignee: Aegis Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.